<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941733</url>
  </required_header>
  <id_info>
    <org_study_id>P998</org_study_id>
    <nct_id>NCT00941733</nct_id>
  </id_info>
  <brief_title>Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia</brief_title>
  <acronym>INPACT-DEEP</acronym>
  <official_title>Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA (Percutaneous Transluminal Angioplasty) for the Treatment of Below the Knee Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with
      critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of
      the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular
      procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard
      (Percutaneous Transluminal Angioplasty) PTA balloon. Patients will be followed with
      pre-study, post-study, and follow-up evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)</measure>
    <time_frame>12 months or at Target Lesion Revascularization (TLR) time</time_frame>
    <description>The difference between minimum lumen diameter (MLD) immediately after Percutaneous Transluminal Angioplasty (PTA) and MLD at 12 months follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants in the amputation free survival population with Clinically driven Target Lesion Revascularization (CD-TLR) at 12 months, CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of participants experiencing all cause death, major amputation and clinically driven Target Lesion Revascularization (CD-TLR) at 6 months. CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amputation Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with a 1 year amputation free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Wound Healing</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with completed wound healing, wound healing as defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Free Survival and Wound Healing</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with a 1 year amputation free survival and wound healing. Wound healing is defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at a specified time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with an amputation free survival and resolved Critical Limb Ischemia (CLI) at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants that experienced death, amputation and clinically driven Target Lesion Revascularization (TLR) at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Sustained Clinical Improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants that experienced primary sustained clinical improvement at 1 year, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Sustained Clinical Improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment by EQ5D</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life assessment by EQ5D at 1 year compared to baseline. EQ-5D is a standardised measure of health status and economic appraisal. The EQ-5D-3L essentially consists of 2 parts:the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.
EQ-5D health states can be converted into a single summary index where 0.0='worst possible outcome' and 1.0='best possible outcome'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Capacity Assessment</measure>
    <time_frame>12 months</time_frame>
    <description>Walking Impairment assessment by WIQ at 1 year compared to baseline. The Walking Impairment Questionnaire (WIQ) is a questionnaire for evaluating walking impairment in patients with peripheral arterial disease (PAD). This can be used to identify patients with significant impairment and to monitor effectiveness of therapeutic interventions. The questionnaire was self-administered by the patients and contains three domains measuring three important factors of walking impairment in patients with intermittent claudication: (1) difficulty walking a distance during the past month, (2) difficulty walking at a certain speed during the past month, (3) symptoms associated with walking impairment. For each separate domain, a subscore was calculated. The total WIQ score was defined as the mean of the three subscores.
A WIQ score of 42.5 or less identified low performers; while a score of 75.5 or more identified high performers. The WIQ score range is 0 (minimum) - 100 (maximum).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAE (Major Adverse Events)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with a MAE (Major Adverse Events) at 1 year. Major Adverse Events, defined as Death of any Cause, Major Amputation of target limb, Minor Amputation of target limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of device success defined as exact deployment of the device according to the instructions for use as documented with suitable imaging modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of patients with a procedural success defined as combination of technical success, device success and absence of procedural complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Days of hospitalization at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with an improvement in percent diameter stenosis (%DS) of the target leasion (TL) assessed by Quantitative Vascular Angiography (QVA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Critical Lower Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: IN.PACT Amphirion™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Standard PTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IN.PACT Amphirion</intervention_name>
    <description>Balloon Angioplasty</description>
    <arm_group_label>Drug Eluting Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA</intervention_name>
    <description>Balloon Angioplasty</description>
    <arm_group_label>Standard PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          -  Age ≥18 years and ≤85 years

          -  Patient or patient's legal representative have been informed of the nature of the
             study, agrees to participate and has signed an Ethical Committee approved consent form

          -  Female patients of childbearing potential have a negative pregnancy test ≤7 days
             before the procedure and are willing to use a reliable method of birth control for the
             duration of study participation

          -  Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior
             to the study procedure with Rutherford Category 4, 5 or 6

          -  Life expectancy &gt;1 year in the Investigator's opinion

        General Angiographic Inclusion Criteria

          -  Reference vessel(s) diameter between 2 and 4 mm

          -  Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in
             one or more main afferent crural vessels including the tibioperoneal trunk

          -  At least one non occluded crural vessel with angiographically documented run-off to
             the foot either direct or through collaterals

        Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment

          -  Angio-target lesion (TL) is one identifiable single solitary or series of multiple
             adjacent lesions with a diameter stenosis (DS) ≥70% and a cumulative length ≤100 mm
             that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both
             edges is mandatory)

          -  Angio-target lesion (TL) is the only lesion in that vessel (only one Angio-TL per
             patient is allowed)

        Exclusion Criteria:

        General Exclusion Criteria

          -  Patient unwilling or unlikely to comply with Follow-Up schedule

          -  Planned major index limb amputation

        General Angiographic Exclusion Criteria

          -  Lesion and / or occlusions located or extending in the popliteal artery or below the
             ankle joint space

          -  Inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA),
             popliteal arteries with length ≥15 cm

          -  Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, Superficial
             Femoral Artery (SFA) and popliteal arteries left untreated

          -  Previously implanted stent in the target lesions(s)

          -  Aneurysm in the target vessel

          -  Acute thrombus in the target limb

        General Procedural Exclusion Criteria

          -  Failure to obtain a &lt;30% residual stenosis in pre-existing, hemodynamically
             significant (≥50% diameter stenosis (DS) and &lt;15 cm length) inflow lesions in the
             ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or
             Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions.

          -  Failure to cross the TL with a 0.014&quot; guide wire

          -  Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation
             therapy, DES as part of the index procedure

        ANGIOGRAPHIC cohort General Exclusion Criteria:

        - Glomerular Filtration Rate (GFR) &lt;30 ml/min except for patients with renal end stage
        disease on chronic haemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Bad Krozingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iris Baumgartner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL St. Jan</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care Center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villa Maria Eleonora Hospital</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24552184</url>
    <description>Zeller et al. Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapoplliteal Arterial Revascularization in CLI - 12-Month Results from the IN.PACT DEEP Randomized trial.Journal of the American College of Cardiology 2014; 64; 15</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <results_first_submitted>August 29, 2014</results_first_submitted>
  <results_first_submitted_qc>October 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2014</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BTK</keyword>
  <keyword>CLI</keyword>
  <keyword>PTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug Eluting Balloon</title>
          <description>IN.PACT Amphirion: Balloon Angioplasty</description>
        </group>
        <group group_id="P2">
          <title>Standard PTA</title>
          <description>Standard PTA balloon: Balloon Angioplasty</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165">1 year follow-up</participants>
                <participants group_id="P2" count="91">1 year follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The total sample size for the study was planned to be 357 subjects, which was intended to fully power the trial for the endpoints of LLL and the composite safety endpoint based on initial estimates of event rates and effect sizes. The endpoint of 12-month TLR was powered to 65% with the indicated sample size.</population>
      <group_list>
        <group group_id="B1">
          <title>Drug Eluting Balloon</title>
          <description>IN.PACT Amphirion: Balloon Angioplasty</description>
        </group>
        <group group_id="B2">
          <title>Standard PTA</title>
          <description>Standard PTA balloon: Balloon Angioplasty</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="239"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="358"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="8.2"/>
                    <measurement group_id="B2" value="71.7" spread="9.9"/>
                    <measurement group_id="B3" value="72.5" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)</title>
        <description>The difference between minimum lumen diameter (MLD) immediately after Percutaneous Transluminal Angioplasty (PTA) and MLD at 12 months follow-up</description>
        <time_frame>12 months or at Target Lesion Revascularization (TLR) time</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)</title>
          <description>The difference between minimum lumen diameter (MLD) immediately after Percutaneous Transluminal Angioplasty (PTA) and MLD at 12 months follow-up</description>
          <population>ITT</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.605" spread="0,775"/>
                    <measurement group_id="O2" value="0.616" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients</title>
        <description>Percentage of participants in the amputation free survival population with Clinically driven Target Lesion Revascularization (CD-TLR) at 12 months, CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s).</description>
        <time_frame>12 months</time_frame>
        <population>Amputation free surviving meaning participants without an amputation at 12 months. This analysis population consists of 196 participants in the Drug Eluting Balloon arm and 107 participants in the Standard PTA arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients</title>
          <description>Percentage of participants in the amputation free survival population with Clinically driven Target Lesion Revascularization (CD-TLR) at 12 months, CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s).</description>
          <population>Amputation free surviving meaning participants without an amputation at 12 months. This analysis population consists of 196 participants in the Drug Eluting Balloon arm and 107 participants in the Standard PTA arm.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Percentage of participants experiencing all cause death, major amputation and clinically driven Target Lesion Revascularization (CD-TLR) at 6 months. CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s)</description>
        <time_frame>6 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (232 participants in the drug eluting balloon arm and 114 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Percentage of participants experiencing all cause death, major amputation and clinically driven Target Lesion Revascularization (CD-TLR) at 6 months. CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s)</description>
          <population>Percentage based on number of evaluable subjects for safety events (232 participants in the drug eluting balloon arm and 114 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.67"/>
                    <measurement group_id="O2" value="15.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amputation Free Survival</title>
        <description>Percentage of participants with a 1 year amputation free survival.</description>
        <time_frame>12 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Amputation Free Survival</title>
          <description>Percentage of participants with a 1 year amputation free survival.</description>
          <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Wound Healing</title>
        <description>Percentage of participants with completed wound healing, wound healing as defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.</description>
        <time_frame>12 months</time_frame>
        <population>Patients with pre-existing wounds and/or occurence of new wounds</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Wound Healing</title>
          <description>Percentage of participants with completed wound healing, wound healing as defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.</description>
          <population>Patients with pre-existing wounds and/or occurence of new wounds</population>
          <units>percentage of patients analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amputation Free Survival and Wound Healing</title>
        <description>Percentage of participants with a 1 year amputation free survival and wound healing. Wound healing is defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at a specified time point.</description>
        <time_frame>12 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (206 participants in the drug eluting balloon arm and 103 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Amputation Free Survival and Wound Healing</title>
          <description>Percentage of participants with a 1 year amputation free survival and wound healing. Wound healing is defined as core lab adjudication of &gt; 50% area/volume reduction of baseline ulcer(s) in the treated leg at a specified time point.</description>
          <population>Percentage based on number of evaluable subjects for safety events (206 participants in the drug eluting balloon arm and 103 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)</title>
        <description>Percentage of participants with an amputation free survival and resolved Critical Limb Ischemia (CLI) at 1 year.</description>
        <time_frame>12 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (205 participants in the drug eluting balloon arm and 103 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)</title>
          <description>Percentage of participants with an amputation free survival and resolved Critical Limb Ischemia (CLI) at 1 year.</description>
          <population>Percentage based on number of evaluable subjects for safety events (205 participants in the drug eluting balloon arm and 103 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)</title>
        <description>Percentage of participants that experienced death, amputation and clinically driven Target Lesion Revascularization (TLR) at 1 year.</description>
        <time_frame>12 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)</title>
          <description>Percentage of participants that experienced death, amputation and clinically driven Target Lesion Revascularization (TLR) at 1 year.</description>
          <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Sustained Clinical Improvement</title>
        <description>Percentage of participants that experienced primary sustained clinical improvement at 1 year, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis population consists of amputation free, clinically driven (target lesion revascularization)TLR free surviving subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Sustained Clinical Improvement</title>
          <description>Percentage of participants that experienced primary sustained clinical improvement at 1 year, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.</description>
          <population>Analysis population consists of amputation free, clinically driven (target lesion revascularization)TLR free surviving subjects</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3"/>
                    <measurement group_id="O2" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Sustained Clinical Improvement</title>
        <description>Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects at 1 year.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis population consists of amputation free, clinically driven (target lesion revascularization)TLR free surviving subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Sustained Clinical Improvement</title>
          <description>Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects at 1 year.</description>
          <population>Analysis population consists of amputation free, clinically driven (target lesion revascularization)TLR free surviving subjects</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6"/>
                    <measurement group_id="O2" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessment by EQ5D</title>
        <description>Quality of life assessment by EQ5D at 1 year compared to baseline. EQ-5D is a standardised measure of health status and economic appraisal. The EQ-5D-3L essentially consists of 2 parts:the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.
EQ-5D health states can be converted into a single summary index where 0.0='worst possible outcome' and 1.0='best possible outcome'.</description>
        <time_frame>12 months</time_frame>
        <population>Effectiveness Analysis sets – all randomized subjects with available data for EQ5D at baseline and 1 year</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessment by EQ5D</title>
          <description>Quality of life assessment by EQ5D at 1 year compared to baseline. EQ-5D is a standardised measure of health status and economic appraisal. The EQ-5D-3L essentially consists of 2 parts:the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.
EQ-5D health states can be converted into a single summary index where 0.0='worst possible outcome' and 1.0='best possible outcome'.</description>
          <population>Effectiveness Analysis sets – all randomized subjects with available data for EQ5D at baseline and 1 year</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6975" spread="0.3080"/>
                    <measurement group_id="O2" value="0.7445" spread="0.3035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Capacity Assessment</title>
        <description>Walking Impairment assessment by WIQ at 1 year compared to baseline. The Walking Impairment Questionnaire (WIQ) is a questionnaire for evaluating walking impairment in patients with peripheral arterial disease (PAD). This can be used to identify patients with significant impairment and to monitor effectiveness of therapeutic interventions. The questionnaire was self-administered by the patients and contains three domains measuring three important factors of walking impairment in patients with intermittent claudication: (1) difficulty walking a distance during the past month, (2) difficulty walking at a certain speed during the past month, (3) symptoms associated with walking impairment. For each separate domain, a subscore was calculated. The total WIQ score was defined as the mean of the three subscores.
A WIQ score of 42.5 or less identified low performers; while a score of 75.5 or more identified high performers. The WIQ score range is 0 (minimum) – 100 (maximum).</description>
        <time_frame>12 months</time_frame>
        <population>Effectiveness Analysis sets – all randomized subjects with available data for Walking Impairment assessment at baseline and 1 year</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Capacity Assessment</title>
          <description>Walking Impairment assessment by WIQ at 1 year compared to baseline. The Walking Impairment Questionnaire (WIQ) is a questionnaire for evaluating walking impairment in patients with peripheral arterial disease (PAD). This can be used to identify patients with significant impairment and to monitor effectiveness of therapeutic interventions. The questionnaire was self-administered by the patients and contains three domains measuring three important factors of walking impairment in patients with intermittent claudication: (1) difficulty walking a distance during the past month, (2) difficulty walking at a certain speed during the past month, (3) symptoms associated with walking impairment. For each separate domain, a subscore was calculated. The total WIQ score was defined as the mean of the three subscores.
A WIQ score of 42.5 or less identified low performers; while a score of 75.5 or more identified high performers. The WIQ score range is 0 (minimum) – 100 (maximum).</description>
          <population>Effectiveness Analysis sets – all randomized subjects with available data for Walking Impairment assessment at baseline and 1 year</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="35.2"/>
                    <measurement group_id="O2" value="75.4" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAE (Major Adverse Events)</title>
        <description>Percentage of participants with a MAE (Major Adverse Events) at 1 year. Major Adverse Events, defined as Death of any Cause, Major Amputation of target limb, Minor Amputation of target limb</description>
        <time_frame>12 months</time_frame>
        <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>MAE (Major Adverse Events)</title>
          <description>Percentage of participants with a MAE (Major Adverse Events) at 1 year. Major Adverse Events, defined as Death of any Cause, Major Amputation of target limb, Minor Amputation of target limb</description>
          <population>Percentage based on number of evaluable subjects for safety events (227 participants in the drug eluting balloon arm and 111 patients in the Standard PTA arm). All randomized subjects experiencing at least one component for the safety endpoint or with follow-up of at least 330 days post-procedure.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Percentage of device success defined as exact deployment of the device according to the instructions for use as documented with suitable imaging modalities</description>
        <time_frame>Day 1</time_frame>
        <population>Number of device deployments</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Percentage of device success defined as exact deployment of the device according to the instructions for use as documented with suitable imaging modalities</description>
          <population>Number of device deployments</population>
          <units>percentage of device deployments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Percentage of technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography</description>
        <time_frame>Day 1</time_frame>
        <population>Number of device deployments</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Percentage of technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography</description>
          <population>Number of device deployments</population>
          <units>percentage of device deployments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                    <measurement group_id="O2" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Percentage of patients with a procedural success defined as combination of technical success, device success and absence of procedural complications</description>
        <time_frame>Day 1</time_frame>
        <population>All randomized subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Percentage of patients with a procedural success defined as combination of technical success, device success and absence of procedural complications</description>
          <population>All randomized subjects with available data</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Hospitalization</title>
        <description>Days of hospitalization at 1 year</description>
        <time_frame>12 months</time_frame>
        <population>All randomized subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Hospitalization</title>
          <description>Days of hospitalization at 1 year</description>
          <population>All randomized subjects with available data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="8.5"/>
                    <measurement group_id="O2" value="4.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)</title>
        <description>Percentage of participants with an improvement in percent diameter stenosis (%DS) of the target leasion (TL) assessed by Quantitative Vascular Angiography (QVA)</description>
        <time_frame>12 months</time_frame>
        <population>Angiographic subgroup only. Angio-target lesion is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis higher than 70% and a cumulative length less than 100 mm that can be covered by a single IN.PACT Amphirion™; and Angio-target lesion is the only lesion in that vessel.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Eluting Balloon</title>
            <description>IN.PACT Amphirion: Balloon Angioplasty</description>
          </group>
          <group group_id="O2">
            <title>Standard PTA</title>
            <description>Standard PTA balloon: Balloon Angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)</title>
          <description>Percentage of participants with an improvement in percent diameter stenosis (%DS) of the target leasion (TL) assessed by Quantitative Vascular Angiography (QVA)</description>
          <population>Angiographic subgroup only. Angio-target lesion is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis higher than 70% and a cumulative length less than 100 mm that can be covered by a single IN.PACT Amphirion™; and Angio-target lesion is the only lesion in that vessel.</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0"/>
                    <measurement group_id="O2" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug Eluting Balloon</title>
          <description>IN.PACT Amphirion: Balloon Angioplasty</description>
        </group>
        <group group_id="E2">
          <title>Standard PTA</title>
          <description>Standard PTA balloon: Balloon Angioplasty</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="239"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Heart valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous polyposis coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Postoperative renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebrovascular stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arteriovenous shunt operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dialysis device insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nail operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral revascularisation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="64" subjects_affected="42" subjects_at_risk="239"/>
                <counts group_id="E2" events="59" subjects_affected="22" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Reperfusion injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyalosis asteroid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteoradionecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Post procedural oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Psychosis postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood cholesterol abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Red blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Scan myocardial perfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Benign spleen tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebrovascular stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Transient acantholytic dermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bile duct stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral revascularisation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial spasm</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vascular shunt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vessel perforation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>Medtronic - CardioVascular</organization>
      <phone>+31433566580</phone>
      <email>kristel.wittebols@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

